10:45 AM EDT, 03/25/2025 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.

Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.

Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.

The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.

Shares of the company were down about 2% in recent trading.

Price: 12.01, Change: -0.24, Percent Change: -1.96